Recruiting Trials

GammaTile Therapy is being evaluated in several clinical studies. For more information on enrolling clinical studies, see below.

STUDY

A Phase 3 Randomized Controlled Trial of Post-Surgical Stereotactic Radiotherapy (SRT) Versus Surgically Targeted Radiation Therapy (STaRT) With GammaTile for Treatment of Newly Diagnosed Metastatic Brain Tumors | NCT04365374

Jeffrey Weinberg, MD

Neurosurgeon

Thomas Beckham, MD, PhD

Radiation Oncologist

LEAD INSTITUTION

The University of Texas –
MD Anderson Cancer Center

STUDY

A Multi-Center Observational Registry Study of GammaTile Surgically Targeted Radiation Therapy (STaRT) in Intracranial Brain Neoplasms | NCT04427384

ENROLLING SITES: 15

Abbott Northwestern Hospital, part of Allina Health
HonorHealth Scottsdale Osborn Medical Center
Indiana University School of Medicine
Miami Cancer Institute | Baptist Health S. Florida
Mount Sinai Health System
Piedmont Atlanta Brain Tumor Center
St. Alphonsus Regional Medical Center
The University of Kansas Health System
University of Minnesota Health
University of North Carolina at Chapel Hill
UT Health San Antonio

LEAD INSTITUTION

UT Southwestern Medical Center | Simmons Cancer Center
ECU Health Medical Center
Westchester Medical Center
Willis-Knighton Health System

STUDY

A Intracavitary Carrier – Embedded Cs-131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study | NCT04690348

Nelson Moss, MD

Neurosurgeon

Kathryn Beal, MD

Radiation Oncologist

Viviane Tabar, MD

Neurosurgeon

LEAD INSTITUTION

Memorial Sloan Kettering
Cancer Center

STUDY

An assessment of GammaTile as an upfront boost at the time of resection in combination with STUPP protocol for patients with newly diagnosed GBM.| NCT05342883

ENROLLING SITES: 3

University of Minnesota Health
Piedmont Atlanta Brain Tumor Center
ECU Health